LPTX — Leap Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $31.24m
- $13.11m
Annual cashflow statement for Leap Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.5 | -40.6 | -54.6 | -81.4 | -67.6 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.24 | 4.39 | 6.19 | 35.1 | 5.96 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.684 | 1 | -0.803 | 2.51 | 1.29 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26 | -35.2 | -49 | -43.8 | -60.3 |
| Capital Expenditures | — | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.025 | 0 | — | 49 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.025 | 0 | — | 49 | — |
| Financing Cash Flow Items | -1.91 | -0.184 | -0.21 | -0.001 | 37.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 74 | 98 | -0.21 | -0.03 | 37.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 48.2 | 62.8 | -49.4 | 5.14 | -23.4 |